evipedia.ai
← Back

Ozone Autohemotherapy for Health & Longevity

Evidence Review created on 09/27/2026 using AI4L / Opus 5.5

Also known as: Major Autohemotherapy, MAH, Major Ozonated Autohemotherapy, O3-MAH, Ozonated Autohemotherapy, O3-AHT, Oxygen-Ozone Autohemotherapy, O2-O3-AHT, Blood Ozonation, Minor Autohemotherapy, Multi-Pass Ozone Therapy, 10-Pass Ozone Therapy, Grande Auto Emo Trasfusione, GAET, Ozone Autohaemotherapy, Ozone Autohemotransfusion

Motivation

Ozone autohemotherapy is a clinic procedure in which a portion of a person’s own blood is drawn, mixed outside the body with a measured blend of medical oxygen and ozone gas, and returned intravenously. Its appeal to health-focused adults rests on the idea that a short, controlled chemical stress prompts the body to strengthen its own defense and repair systems, the same brief beneficial stress logic behind exercise, sauna and cold exposure.

The procedure has been used for decades in clinics in Germany, Italy, Spain and Cuba, and longevity clinics in North America now offer it, often in higher-dose versions that treat the blood in repeated rounds during one visit. Studies have explored nerve pain after shingles, sleep, and lingering tiredness after viral illness, while United States regulators, who have no revenue stake in the question, describe ozone as a toxic gas without a proven medical use.

This review examines what ozone autohemotherapy may improve, what harms it can cause, how it is typically delivered, and how the quality and sources of the evidence shape what can be concluded for health and longevity.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews and commentary on ozone autohemotherapy from critics, proponents and independent reviewers.

None of the six priority experts has published dedicated content on ozone autohemotherapy. Peter Attia’s and Rhonda Patrick’s sites return no relevant results; Andrew Huberman has no episode on the topic; Chris Kresser’s site contains only a passing guest remark; Life Extension mentions it only briefly within a radiation-therapy protocol; and Lifespan.io lists only a clinic directory entry. These passing mentions lack the depth required for inclusion.

Grokipedia

Ozone therapy

The general ozone-therapy article; it covers autohemotherapy alongside other routes, plus history, proposed mechanisms, regulatory status and reported complications such as gas embolism (gas bubbles blocking blood vessels), rather than autohemotherapy alone.

Examine

No Examine.com article on ozone autohemotherapy or ozone therapy exists; the site search returned only an unrelated condition page. Examine.com focuses on supplements and nutrition and does not typically cover clinic-administered procedures such as blood ozonation.

ConsumerLab

No ConsumerLab article on ozone autohemotherapy exists; the site search returned only items on air purifiers, produce washes and regulatory warnings. ConsumerLab tests consumer health products and does not typically cover clinic-administered procedures.

Systematic Reviews

This section lists systematic reviews and meta-analyses covering ozone autohemotherapy’s claimed benefits and reported safety.

No systematic review or meta-analysis addresses the principal risks of ozone autohemotherapy (gas embolism, red blood cell rupture and infection transmission); the first two papers above pooled adverse events only within their included trials, the umbrella review found safety reporting too inconsistent for firm conclusions, and the serious harms are covered by case reports and a scoping review cited under Potential Risks & Side Effects.

Mechanism of Action

Ozone is too reactive to circulate. When an oxygen-ozone mix meets drawn blood, it reacts within seconds with plasma antioxidants (uric acid, vitamin C) and with polyunsaturated fats, producing two classes of messengers (Bocci, 2004):

  • Hydrogen peroxide: a short-lived signal that enters blood cells and briefly shifts their redox balance (the ratio of oxidizing to protective reducing molecules).
  • Lipid oxidation products: longer-lived aldehydes such as 4-hydroxynonenal that travel through the body after reinfusion.

These messengers are proposed to activate Nrf2 (nuclear factor erythroid 2-related factor 2, the master switch for antioxidant and detoxification genes), raising protective enzymes such as superoxide dismutase (an enzyme that neutralizes the superoxide free radical) and catalase (an enzyme that breaks down hydrogen peroxide); a small study in healthy volunteers by clinic-affiliated authors found a transient Nrf2 rise after treatment (Re et al., 2014). Proponents also describe dampened NF-κB (nuclear factor kappa B, the master switch for inflammatory genes) and better red-cell oxygen release.

Competing view: critics argue repeated oxidant exposure mainly consumes antioxidants; red-cell glutathione (the main cellular antioxidant) fell after nine sessions in a controlled study (Tylicki et al., 2003).

Pharmacology: ozone acts non-selectively and never reaches tissues itself; only its products distribute. Hydrogen peroxide lasts under a minute, while lipid products are cleared within hours by glutathione S-transferases (enzymes that tag toxic molecules for removal) and aldehyde dehydrogenases (enzymes that detoxify aldehydes), without known cytochrome P450 (the liver’s main drug-processing enzymes) involvement.

Historical Context & Evolution

Ozone was identified by Christian Friedrich Schönbein in 1840 and first used as a disinfectant, including for wound irrigation in World War I. Its original intended use was therefore antiseptic, not systemic. In the 1950s and 1960s, German physicians, notably Hans Wolff, developed major autohemotherapy (MAH, treating roughly 100 to 200 mL of blood and reinfusing it) for circulatory disorders and infections.

In 1976, the United States Food and Drug Administration, a regulator without direct revenue from the question, classified ozone as a toxic gas with no known medical application, a position it retains. In the 1990s, Velio Bocci at the University of Siena studied how ozone reacts in blood and defined dose ranges; his reappraisal found no toxicity at standard doses but acknowledged that good clinical trials were lacking, since practice was mainly in private clinics (Bocci, 1994).

Harms then reshaped practice: a fatal gas embolism (Marchetti & La Monaca, 2000) and a hepatitis C cluster in Rome (Faustini et al., 2005) prompted ozone-therapy societies, whose members earn revenue from the procedure, to reject direct gas injection and to stress sterile single-use equipment. Small randomized trials followed in eye disease, leg-artery disease and pain, and in 2020 many hospitals tested it in COVID-19, with mixed results.

It entered health optimization when longevity clinics reframed it as a brief beneficial stress that activates repair pathways, adding higher-dose multi-pass and blood-circuit variants. Neither regulators’ skepticism nor proponents’ enthusiasm is the final word; controlled evidence remains limited on both sides.

Expected Benefits

High 🟩 🟩 🟩

Adding autohemotherapy to standard drugs reduced zoster-associated pain (the burning nerve pain during and after shingles, including postherpetic neuralgia, pain lasting beyond three months). A meta-analysis of 20 randomized trials (1,519 patients) found large pain reductions, better quality of life and lower interleukin-6 (an inflammatory signaling protein) (Wu et al., 2026); a 98-patient trial showed benefits lasting three months (Hu et al., 2018). Trials were Chinese, mostly unblinded and heterogeneous, with evidence certainty rated very low to moderate.

Magnitude: Pain scores fell by a standardized mean difference (effect size in standard-deviation units) of −1.77 (95% confidence interval, the range likely to contain the true value, −2.16 to −1.37); the pain-relief response rate rose by a risk ratio (ratio of event rates between groups) of 1.21.

Better Sleep Quality in Chronic Pain Conditions

In a placebo-controlled trial of 54 people with fibromyalgia (a chronic widespread-pain disorder), ten sessions improved Pittsburgh Sleep Quality Index scores (a validated sleep questionnaire) more than a sham (simulated) procedure (Sucuoğlu & Soydaş, 2023). A 118-patient randomized trial in insomnia with myofascial pain syndrome (pain arising from muscle trigger points) found better insomnia severity, pain and mood up to six months with autohemotherapy added to drugs (Shen et al., 2022). Both trials were small and single-center; none studied healthy sleepers.

Magnitude: Validated sleep scores improved more than in control arms during three-week to five-week courses, with the gain persisting to six months in one trial; the published reports state only that the differences were unlikely to be due to chance, with no effect-size figure.

Medium 🟩 🟩

Fewer Lingering Symptoms After Viral Illness

In a pilot randomized trial of 73 adults with lingering symptoms after COVID-19, adding MAH to usual care improved symptom scores, six-minute walk distance and inflammation, with better response when C-reactive protein (CRP, a blood marker of inflammation) was high (He et al., 2024). Uncontrolled series in chronic fatigue syndrome (a long-lasting disabling fatigue illness) report large gains but come from Italian ozone-society clinicians who deliver the treatment (Tirelli et al., 2021). No sham-controlled trial exists.

Magnitude: 71% of treated versus 45% of control patients achieved at least a 50% reduction in symptom score.

Slower Vision Loss in Dry Macular Degeneration

Dry age-related macular degeneration (gradual central vision loss from retinal aging) is a leading cause of late-life visual decline. In a randomized trial of 140 patients, 27 MAH sessions over 12 months preserved or improved visual acuity while multivitamin-treated controls declined, and oxidative-stress markers fell (Borrelli et al., 2012). The trial was unblinded, used a weak comparator, included the method’s leading proponent as author and has not been replicated.

Magnitude: At 12 months, 25% of treated eyes gained at least one line of acuity versus 0% of controls, and 0% versus 40% lost two or more lines.

Longer Walking Distance in Leg-Artery Disease

Peripheral arterial disease (narrowed leg arteries causing pain on walking) limits mobility in older adults. In a single-blind crossover trial (each patient received both treatments in turn) in 10 hemodialysis patients (people whose blood is machine-filtered for kidney failure), ozonated autohemotherapy lengthened treadmill walking beyond an identical oxygen-only procedure (Biedunkiewicz et al., 2004). The trial was tiny and confined to dialysis patients, so transfer to healthy adults is uncertain.

Magnitude: Maximal walking distance rose 22.7% and pain-free walking distance 62.8% relative to the oxygen control.

Better Recovery After Ischemic Stroke ⭕️ Not Central to Health & Longevity

This benefit bears on acute stroke care, not on health optimization. In a 62-patient randomized trial with an oxygen-placebo arm, five days of autohemotherapy started within 24 hours of stroke improved neurological, daily-function and cognitive scores and lowered markers of nerve-cell injury (Cheng et al., 2025). It is a single-center, unreplicated trial.

Magnitude: Stroke-severity scores fell 30%, daily-function scores rose 25% and cognitive scores rose 20% relative to the control group.

Hearing Recovery After Sudden Hearing Loss ⭕️ Not Central to Health & Longevity

This bears on treating an acute ear emergency, not on health optimization. In a double-blind placebo-controlled trial of 45 adults with sudden sensorineural hearing loss (abrupt inner-ear hearing loss of unclear cause), ten twice-weekly sessions of 100 mL blood ozonation improved hearing thresholds, speech recognition and recovery rates more than placebo (Ragab et al., 2009). It is a single-center trial with a small placebo arm (15 patients) and no independent replication.

Magnitude: Significant hearing recovery occurred in 77% of treated versus 40% of placebo patients.

Low 🟩

Acute COVID-19 Outcomes ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

This bears on hospital infection care, not health optimization. One meta-analysis reported lower mortality (Shang et al., 2023); another found this only in non-randomized studies (Setyo Budi et al., 2022). Net: randomized evidence shows no survival benefit.

Magnitude: Mortality risk ratio 0.38 in one pooled analysis, but no significant mortality difference in randomized trials.

Fibromyalgia Symptom Relief ⚠️ Conflicted

Uncontrolled series report large pain and function gains (Tertemiz et al., 2025), but the only placebo-controlled trial found no difference in overall fibromyalgia impact versus sham (Sucuoğlu & Soydaş, 2023). Net: benefit beyond placebo is unconfirmed.

Magnitude: Pain scores fell from 7.8 to 4.8 (0 to 10 scale) in 72 uncontrolled patients; the sham-controlled trial found no between-group difference in total impact score.

Improved Cognition and Smell in Mild Cognitive Impairment

In a retrospective study of 81 adults with mild cognitive impairment (memory and thinking decline beyond normal aging, short of dementia), ten sessions were followed by better smell and one cognitive test score (Micarelli et al., 2026). No treated control group existed.

Magnitude: The share with normal smell rose from 32.1% to 50.6%; a second cognitive test (Mini-Mental State Examination) did not change.

Lower LDL Cholesterol

In 12 hemodialysis patients, nine sessions lowered low-density lipoprotein cholesterol (LDL, the main cholesterol carrier linked to artery disease) versus pre-treatment values (Tylicki et al., 2004). The comparison was to baseline, not a parallel control group.

Magnitude: LDL fell 17.7% and total cholesterol 8.3% from baseline.

Fewer Amputations From Diabetic Foot Ulcers ⭕️ Not Central to Health & Longevity

This bears on diabetic wound care, not health optimization. A review of 12 randomized trials found fewer amputations with ozone, but pooled topical and systemic routes, including blood-based ones (Wen et al., 2022). Complete healing did not improve, and the effect of autohemotherapy alone is unclear.

Magnitude: Amputation risk ratio 0.36 across mixed ozone routes, with no gain in complete wound healing.

Hepatitis C Viral Clearance ⭕️ Not Central to Health & Longevity

This bears on chronic viral hepatitis, now curable with modern antiviral drugs. In a non-randomized study, 40 patients receiving combined autohemotherapy and other ozone routes cleared virus more often than 12 controls (Zaky et al., 2011).

Magnitude: Virus became undetectable in 44.4% after 60 sessions versus 8% of controls.

Speculative 🟨

Activation of Cellular Stress-Defense Pathways

In healthy volunteers, three sessions transiently raised Nrf2 and increased antioxidant enzymes (Re et al., 2014). These are unvalidated biomarkers with no demonstrated link to health or aging outcomes.

Slowing of Biological Aging

Ozone-society reviewers, who earn treatment revenue, propose effects on mitochondria, worn-out non-dividing cells and inflammation relevant to aging (Chirumbolo et al., 2025). The basis is mechanistic and animal work; no human aging data exist.

Better Exercise Performance and Recovery

Two small trials in healthy adults, on aerobic capacity (NCT06217549) and post-exercise muscle damage (NCT07728422), are completed but unpublished. The basis remains mechanistic.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant has been tested as a predictor of benefit. Variants in NFE2L2 (the gene encoding Nrf2) or GSTM1 (a gene for a detoxifying glutathione enzyme) could plausibly alter response; this remains untested.
  • Baseline inflammation: In the post-COVID trial, people with elevated C-reactive protein responded better (He et al., 2024), suggesting healthy adults with low inflammation may gain less.
  • Baseline oxidative status: Measurable antioxidant shifts appear mainly in people with high oxidative burden, such as dialysis (Tylicki et al., 2003) or macular-degeneration patients (Borrelli et al., 2012); healthy volunteers show only a transient Nrf2 rise (Re et al., 2014).
  • Sex: In a 200-patient chronic fatigue series by ozone-society clinicians, women improved more than men, especially at younger ages (Chirumbolo et al., 2021); controlled sex comparisons are lacking.
  • Pre-existing conditions: Nearly all positive trials enrolled people with a disease (shingles pain, fibromyalgia, leg-artery disease, macular degeneration); benefits in healthy adults are unstudied.
  • Age: Most trial participants were middle-aged or older, so evidence fits older adults better; age-related declines in antioxidant capacity could either amplify or blunt the response.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the randomized trials report few adverse events, and serious harms are documented only in case reports and one uncontrolled outbreak investigation.

Medium 🟥 🟥

Bruising at the Needle Site

Drawing 100–200 mL of blood and reinfusing it through a vein can leave bruising (blood leaking under the skin) around the puncture. In a randomized stroke trial, puncture-site bruising occurred in both the ozone and the oxygen-only arms and resolved within a week without stopping treatment (Cheng et al., 2025). The cause is the needle puncture rather than ozone itself; anticoagulant or antiplatelet medications (blood thinners), low platelets and fragile veins raise the risk.

Magnitude: Bruising affected 8 of about 20 ozone-treated and 6 of about 20 oxygen-treated patients over five daily sessions, all resolving within a week.

Low 🟥

Gas Embolism, Stroke and Death

Gas entering the circulation, via faulty reinfusion or direct gas injection, can block brain or lung vessels. A fatal embolism occurred during autohemotherapy (Marchetti & La Monaca, 2000); brain cases involve a patent foramen ovale (a small opening between heart chambers) (Casale et al., 2026). Evidence is case reports.

Magnitude: Risk concentrates with direct intravenous gas injection or faulty reinfusion and, for brain embolism, with a patent foramen ovale; the literature reports no incidence figure.

Red Blood Cell Rupture, High Potassium and Kidney Injury

Ozone above about 60 µg/mL can rupture red cells (hemolysis), releasing potassium and, when severe, causing kidney failure (Casale et al., 2026). A woman with kidney disease developed hyperkalemia (dangerously high blood potassium) and a heart-rhythm pause (Tang et al., 2017). Multi-pass protocols expose more blood at higher concentrations.

Magnitude: Risk rises with concentrations above about 60 µg/mL, multi-pass exposure, inherited red-cell enzyme deficiency and kidney disease; the literature reports no incidence figure.

Bloodborne Infection Transmission

In a Rome outpatient clinic, hepatitis C virus infections clustered among patients receiving their own ozone-enriched blood, likely spread between patients during crowded sessions (Faustini et al., 2005). The risk stems from breaches in sterile technique, not ozone itself.

Magnitude: 19.4% of tested patients carried hepatitis C virus versus 0.9% of the regional population.

Allergic and Fainting Reactions During Reinfusion

A scoping review of systemic ozone safety found fainting and low blood pressure with rapid reinfusion, and anaphylaxis (severe allergic reaction) linked to equipment materials (Casale et al., 2026). Evidence is case-level.

Magnitude: Fainting and low blood pressure rise with rapid reinfusion, and anaphylaxis tracks specific equipment materials; the literature reports no incidence figure.

Myocardial Infarction After Treatment

Myocardial infarction (heart attack) has followed sessions, attributed to ozone’s proposed vessel-constricting and clot-promoting effects. A 46-year-old man without risk factors had a blocked heart artery after autohemotherapy (Üreyen et al., 2015); a woman fainted and then had a myocardial infarction (Bingham & Platt, 2020). Evidence is case reports.

Magnitude: Not quantified in available studies. Only isolated case reports exist, with no registry or controlled denominator.

Speculative 🟨

Cumulative Antioxidant Depletion

Red-cell glutathione fell after nine sessions in a controlled study (Tylicki et al., 2003). Whether years of maintenance sessions erode defenses is untested; the basis is an unvalidated biomarker.

Transient Flu-Like Reactions

Clinicians describe short-lived fatigue or flu-like symptoms after sessions, sometimes labeled Herxheimer-type reactions (a temporary flare attributed to microbial die-off). The basis is isolated clinical reports; no controlled data exist.

Risk-Modifying Factors

  • Genetic polymorphisms: G6PD deficiency (glucose-6-phosphate dehydrogenase deficiency, an inherited enzyme defect leaving red cells vulnerable to oxidants) sharply raises hemolysis risk; it is common in African, Mediterranean, Middle Eastern and Asian ancestry.
  • Baseline potassium and kidney function: Potassium above 5.0 mmol/L or reduced kidney filtration raises the risk that hemolysis-released potassium becomes dangerous.
  • Baseline blood counts: Anemia or low platelets increase vulnerability to red-cell loss, bruising and bleeding at the puncture site.
  • Sex: No sex difference in serious harms is reported; women faint more often during blood draws, and pregnancy is a standard exclusion.
  • Pre-existing conditions: Patent foramen ovale, heart rhythm disorders, uncontrolled overactive thyroid and bleeding disorders raise the consequences of embolism, stress or bleeding.
  • Age: Older adults more often have fragile veins, reduced kidney function and potassium-raising medications, increasing hyperkalemia and bruising risk.

Key Interactions & Contraindications

  • Anticoagulants and antiplatelets (blood thinners such as warfarin, apixaban, rivaroxaban, clopidogrel): Caution. Citrate or heparin in the collection bottle plus the blood-draw needle puncture raise bruising and bleeding risk. Mitigation: citrate rather than heparin, clotting checks, and prolonged puncture-site pressure.
  • Potassium-raising drugs (ACE inhibitors (angiotensin-converting enzyme inhibitors, blood-pressure drugs) such as lisinopril; ARBs (angiotensin receptor blockers, blood-pressure drugs) such as losartan; spironolactone): Caution. These drugs can compound hemolysis-released potassium, risking hyperkalemia. Mitigation: potassium checks before and during a course.
  • Oxidant drugs (dapsone, primaquine, nitrofurantoin, rasburicase): Absolute contraindication in G6PD deficiency; caution otherwise. Additive oxidative stress can trigger hemolysis. Mitigation: G6PD testing before the first session.
  • Over-the-counter analgesics (pain-relief medications such as aspirin, ibuprofen, naproxen): Monitor. Added platelet inhibition increases bruising at the puncture site. Mitigation: firm pressure; dose changes are usually unnecessary.
  • High-dose antioxidant supplements (vitamin C, N-acetylcysteine, alpha-lipoic acid): Monitor. Proponents suggest large doses just before a session may blunt the intended oxidative signal; intravenous vitamin C adds hemolysis risk in G6PD deficiency. Mitigation: at least 24 hours between high-dose antioxidants and a session.
  • Supplements with antiplatelet effects (high-dose fish oil, ginkgo, vitamin E): Monitor. Additive bruising and bleeding risk at the needle-puncture site. Mitigation: firm pressure, with extra care when combined with anticoagulants.
  • Supplements acting on the same defense switch (sulforaphane, curcumin): Monitor. They also activate Nrf2, so effects may add; no harm is documented. Mitigation: one change at a time, so response can be judged.
  • Potassium supplements and salt substitutes (potassium chloride): Caution. Additive hyperkalemia risk with hemolysis. Mitigation: a pause on session days when kidney function is reduced.
  • Other oxidative therapies (hyperbaric oxygen, intravenous hydrogen peroxide, ultraviolet blood irradiation): Caution. Stacked oxidative load of uncertain safety. Mitigation: separate days and no same-week dose escalation.

Populations who should avoid Ozone Autohemotherapy:

  • G6PD deficiency (enzyme activity below the laboratory reference range)
  • Pregnancy
  • Uncontrolled hyperthyroidism (overactive thyroid; suppressed thyroid-stimulating hormone with elevated free thyroxine)
  • Platelet count below 50,000/µL or inherited bleeding disorders
  • Hemoglobin below 10 g/dL
  • Advanced kidney disease (estimated filtration rate below 30 mL/min/1.73 m²) or potassium above 5.0 mmol/L
  • Recent myocardial infarction (under 90 days), unstable angina (chest pain at rest from poor heart blood flow) or uncontrolled arrhythmia (irregular heartbeat)
  • Known patent foramen ovale or other right-to-left heart shunt (an abnormal passage letting blood bypass the lungs)
  • Allergy to citrate, or prior heparin-induced thrombocytopenia (platelet collapse triggered by heparin) when heparin is used

Risk Mitigation Strategies

  • G6PD screening: A single G6PD activity test before the first session prevents oxidant-triggered hemolysis in people with the inherited deficiency.
  • Concentration ceiling: Keeping ozone at 10–40 µg/mL, and never above 60 µg/mL, limits hemolysis and hyperkalemia, per the range recommended in a scoping review of autohemotherapy safety (Casale et al., 2026).
  • Gradual escalation: Starting at 10–20 µg/mL and rising 5–10 µg/mL per session exposes early intolerance and lowers hemolysis risk.
  • Closed, single-use sterile kits: One sealed kit per patient per session, with no shared bottles, lines or gas syringes, prevents hepatitis and other bloodborne transmission.
  • No direct gas injection: Choosing clinics that only reinfuse ozonated blood, never use intravenous gas injection, prevents gas embolism, stroke and death.
  • Slow reinfusion: Reinfusing over 15–20 minutes (under about 50 drops per minute) reduces fainting and low blood pressure.
  • Potassium and kidney checks: Baseline potassium and kidney-function tests, repeated after 3–5 sessions in kidney disease, detect hyperkalemia early.
  • Hydration and a light meal: Drinking 500 mL of water and eating beforehand reduces fainting during blood draw and reinfusion.
  • Maintenance limits: Limiting ongoing sessions to no more than monthly between courses reduces possible cumulative antioxidant depletion.

Therapeutic Protocol

  • Standard major autohemotherapy: Developed by Hans Wolff and dose-standardized by Velio Bocci: 100–200 mL blood with sodium citrate, mixed with equal gas volume at 10–40 µg/mL, reinfused over 15–20 minutes (Casale et al., 2026).
  • Blood volume scaling: Some protocols scale blood volume to body weight (about 1.3 mL per kg) to standardize ozone dose per person (Re et al., 2014).
  • Dose escalation: Courses typically start at 10–20 µg/mL and rise 5 µg/mL per session to 30–40 µg/mL (Tertemiz et al., 2025).
  • Course length: Two sessions weekly for 10–15 sessions, then optional maintenance every 2–4 weeks; macular-degeneration benefits used 27 sessions over a year (Borrelli et al., 2012).
  • Madrid Declaration approach: Consensus practice popularized by the International Scientific Committee of Ozone Therapy, whose members earn revenue from ozone treatment; sessions follow the 10–40 µg/mL range and G6PD screening summarized in a scoping review (Casale et al., 2026).
  • Italian society approach: Promoted by Marianno Franzini’s Italian ozone-therapy society, whose members deliver and teach the procedure; it emphasizes standardized devices and practitioner certification.
  • High-dose multi-pass approach: Associated with Austrian physician Johann Lahodny; repeated rounds of about 200 mL blood at higher concentrations in one visit. Far less studied than standard sessions.
  • Continuous-circuit approach: Extracorporeal blood oxygenation and ozonation, developed by Nicola Di Paolo in Siena, ozonates blood through a dialysis-like circuit (Di Paolo et al., 2005).
  • Minor autohemotherapy: 5–10 mL ozonated blood given by intramuscular injection, promoted as immune stimulation by German ozone-society practitioners such as Renate Viebahn-Haensler, whose members earn treatment revenue; clinical evidence is minimal.
  • Conventional alternatives: For the same targets, licensed options include medications for nerve pain, supervised walking programs, and antioxidant eye-vitamin formulations, each with larger evidence bases and different risks.
  • Time of day: No study compares timing; sessions occur in daytime clinic hours, and a light meal beforehand is associated with less fainting.
  • Half-life: Ozone reacts within seconds and hydrogen peroxide within a minute; lipid products persist for hours, and proposed gene-level effects last days, underlying twice-weekly spacing.
  • Single versus split dosing: Each session is one complete dose; dosing is split across sessions over weeks, not within a day, except in multi-pass protocols.
  • Genetic polymorphisms: G6PD deficiency rules out treatment; no other gene variant is known to guide dose selection.
  • Sex: Women responded better in a chronic fatigue series (Chirumbolo et al., 2021); weight-scaled blood volume adjusts for women’s usually smaller blood volume.
  • Age: Older adults typically start at lower concentrations with slower reinfusion, after checking kidney function and potassium.
  • Baseline biomarkers: Elevated C-reactive protein predicted better response in the post-COVID trial (He et al., 2024); low baseline inflammation may predict smaller gains.
  • Pre-existing conditions: Kidney disease, heart failure or anemia call for smaller blood volumes, lower concentrations and closer monitoring.

Discontinuation & Cycling

  • Short-term versus ongoing use: Trials used defined courses of 10–27 sessions; longevity clinics offer indefinite maintenance, which no study has evaluated.
  • Withdrawal effects: No withdrawal or rebound effects are reported after stopping.
  • Tapering: Not required; some practitioners step down from twice weekly to every 2–4 weeks before stopping.
  • Durability: Shingles pain and sleep gains persisted three to six months after courses ended (Hu et al., 2018; Shen et al., 2022), while vision benefits accrued only with ongoing sessions (Borrelli et al., 2012).
  • Cycling: Practitioners commonly cycle courses (for example, one course every 3–6 months) to avoid possible antioxidant depletion; no trial has tested cycling versus continuous use.

Sourcing and Quality

  • Medical-grade oxygen and certified generator: Medical ozone is generated from medical oxygen by a medical-device generator with photometric (light-based) concentration measurement; consumer generators lack dose accuracy.
  • Ozone-resistant materials: Glass bottles or certified ozone-resistant bags are used; ordinary plastics can release degradation products, and the glass-versus-bag hemolysis question is debated within ozone societies.
  • Closed single-use sterile kits: Sealed, single-patient kits prevent bloodborne infection transmission.
  • Established manufacturers: Long-standing German medical generator makers such as Hänsler Medical and Herrmann Apparatebau supply European clinics; device certification status differs by country.
  • Practitioner training: Reputable providers are licensed physicians trained through ozone-therapy societies, which themselves earn revenue from certification and promotion.
  • Clinic red flags: Direct intravenous gas injection, reused equipment, group sessions sharing supplies, or concentrations above 60 µg/mL indicate unsafe practice.

Practical Considerations

  • Time to effect: Pain and sleep changes appeared within one to three weeks of starting a course (Shen et al., 2022); vision effects took 6–12 months of ongoing sessions (Borrelli et al., 2012).
  • Common pitfalls: Assuming disease-trial benefits apply to healthy adults, skipping G6PD testing, choosing clinics that inject gas directly, and stacking with same-day intravenous vitamin C.
  • Regulatory status: The U.S. Food and Drug Administration, which has no revenue stake, deems ozone a toxic gas with no known medical application (21 CFR 801.415); practice persists under physician licensure, and several European countries regulate it as a medical procedure.
  • Cost and accessibility: Advertised prices run roughly USD 150–350 per standard session and USD 500–1,500 for multi-pass sessions; insurers rarely pay.
  • Payer and funding bias: Insurers have an incentive to favor cheaper generic alternatives over repeated ozone courses, and unpatentable ozone attracts no drug-maker trials, leaving research and guidance mostly to ozone societies and clinics — a structural bias in funding and guidelines.
  • Time commitment: Each session takes 45–60 minutes, twice weekly during a course, which adds meaningful travel and scheduling burden.

Interaction with Foundational Habits

  • Sleep: Potentiating in chronic pain: two randomized trials found better sleep scores (Sucuoğlu & Soydaş, 2023; Shen et al., 2022), possibly through reduced pain and inflammation. No data exist in healthy sleepers; daytime sessions avoid disrupting evening routines, and a completed trial in post-stroke insomnia (NCT05508113) remains unpublished.
  • Nutrition: Indirect: blood antioxidants from diet (vitamin C, uric acid, vitamin E, glutathione precursors from protein) buffer ozone’s reaction. A balanced diet supports this; very high-dose antioxidant supplements just before sessions may blunt the signal. A light meal and fluids beforehand reduce fainting.
  • Exercise: Possibly additive, since both act as brief beneficial stressors, but untested: trials on aerobic capacity (NCT06217549) and muscle damage recovery are unpublished. Intense training within hours of a session adds puncture-site bruising and fainting risk.
  • Stress management: Indirect: the insomnia and muscle-pain trial (Shen et al., 2022) reported improved mood and less fatigue, but no study measured cortisol or stress physiology. Needle anxiety increases fainting; calm breathing and reclining during reinfusion reduce this.

Monitoring Protocol & Defining Success

Before a first course, baseline testing establishes eligibility and a reference point: G6PD activity, a complete blood count, potassium and kidney function, thyroid status, inflammation, cholesterol, and screening for bloodborne viruses, which also documents status in case of a clinic-related infection. People with kidney disease or on potassium-raising drugs typically also have potassium checked on treatment days.

Ongoing monitoring follows a fixed cadence: potassium and complete blood count after the first 3–5 sessions, again at the end of each 10–15-session course, then every 3–6 months during maintenance; inflammation and cholesterol at course end and every 6–12 months; blood tests for bloodborne viruses yearly for people receiving repeated sessions. Success means measurable improvement in the targeted symptom or marker compared with the person’s own baseline, without hemolysis or potassium problems.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
G6PD activity Within laboratory reference range (normal activity) Rules out hemolysis-prone enzyme deficiency Test once before first session; results can be falsely normal right after a hemolysis episode
Hemoglobin Men 14–16 g/dL; women 13–15 g/dL Detects red-cell loss or hemolysis Conventional range about 12–17.5 g/dL; pair with lactate dehydrogenase and haptoglobin (markers of red-cell breakdown) if hemoglobin falls
Platelet count 200,000–350,000/µL Detects bleeding risk Conventional range 150,000–450,000/µL; treatment is withheld below 50,000/µL
Potassium 4.0–4.5 mmol/L Detects hyperkalemia from hemolysis Conventional range 3.5–5.0 mmol/L; hemolyzed samples read falsely high; pre-session checks if kidney function is reduced
eGFR Above 90 mL/min/1.73 m² Gauges ability to clear potassium eGFR is estimated glomerular filtration rate, a kidney-function measure; conventional “normal” is above 60
hs-CRP Below 1.0 mg/L Tracks inflammation; high values predicted better response hs-CRP is high-sensitivity C-reactive protein; conventional cutoff below 3.0 mg/L; values rise during acute infection
TSH 1.0–2.0 mIU/L Excludes overactive thyroid TSH is thyroid-stimulating hormone; conventional range 0.4–4.5 mIU/L; morning draw preferred
LDL cholesterol Below 100 mg/dL (below 70 mg/dL if high cardiovascular risk) Tracks the cholesterol effect reported in one small study (Tylicki et al., 2004) Fasting or non-fasting acceptable; pair with apolipoprotein B (the particle-count protein)
Hepatitis B, hepatitis C and HIV serology Negative Documents baseline and detects clinic-acquired infection HIV is human immunodeficiency virus; repeat yearly with repeated sessions
Red-cell glutathione No established target; track change from own baseline Detects possible antioxidant depletion Specialty test; most useful with long-term maintenance use

Qualitative markers:

  • Pain intensity on a 0–10 scale, especially for nerve or widespread pain
  • Sleep quality, including time to fall asleep and night waking
  • Daytime energy and fatigue level
  • Exercise tolerance, such as walking distance or recovery time
  • Mood and mental clarity
  • Bruising, fainting, or flu-like symptoms after sessions

Emerging Research

  • Muscle aging in fibromyalgia: A sham-controlled trial (NCT07680621) will give 60 patients exercise plus MAH or sham (0.1 µg/mL), measuring fibromyalgia impact, grip strength and muscle ultrasound over three months; it could strengthen or weaken the case for muscle-relevant benefits.
  • Palliative systemic ozone cohort: A recruiting 120-patient study in Spain (NCT07325851) tracks quality of life, autonomic function (the nervous system’s automatic control of heart rate and circulation) and gut microbiome with autohemotherapy and other routes, building on earlier quality-of-life gains in cancer survivors (Clavo et al., 2023).
  • Exercise and recovery: Two completed trials, aerobic capacity in 17 healthy men (NCT06217549) and muscle-damage recovery in 32 adults (NCT07728422), await publication; null results would weaken performance claims.
  • Cognitive decline: Smell and cognitive gains in mild cognitive impairment (Micarelli et al., 2026) came without a control group; a randomized sham-controlled trial could confirm or refute them.
  • Post-COVID fatigue replication: A retrospective 40-patient study found fatigue, mood and quality-of-life gains (Kuculmez, 2026); larger sham-controlled trials than the pilot randomized trial (He et al., 2024) are still absent.
  • Safety registries: A 2026 scoping review found serious-harm incidence unquantifiable without prospective registries (Casale et al., 2026); registry data could either reassure or reveal underreported harms.
  • Container and hemolysis debate: Ozone-society authors, whose members earn revenue from treatment, disagree on whether container type drives hemolysis (Franzini et al., 2024; Martinelli et al., 2025); direct comparative data could change protocol standards.
  • Unreplicated eye-disease finding: The only macular-degeneration trial (Borrelli et al., 2012) awaits independent, blinded replication; failure to replicate would remove the strongest aging-relevant benefit.

Conclusion

Ozone autohemotherapy draws a person’s blood, briefly mixes it with ozone gas and returns it, aiming to trigger the body’s own defense and repair systems. For health-focused adults willing to invest time and money, the evidence is uneven: the most consistent human evidence concerns relief of nerve pain after shingles and better sleep in people with chronic pain. Single small trials suggest fewer lingering symptoms after viral illness, slower vision loss in an age-related eye disease, longer walking distance with narrowed leg arteries, and better stroke recovery. Claims that it slows aging itself rest on laboratory and animal work, not human outcomes.

Serious harms appear rare in controlled studies but are real: gas bubbles entering the circulation have caused strokes and a death, red blood cell damage can raise potassium dangerously, and poor hygiene has spread hepatitis between patients. These risks depend heavily on clinic practice, dose and an inherited enzyme deficiency.

The evidence base is small, often lacks placebo comparisons, and comes largely from ozone-therapy societies and clinics whose members earn income from the treatment; the regulator that rejects its medical value has no such stake. Because the gas cannot be patented and is cheap, neither insurers nor drug makers have reason to fund large trials, leaving most questions open. For now, the case for this treatment in healthy people seeking longer, healthier lives is unproven, while its value for specific painful or disease-related conditions remains plausible but uncertain.

Top - Benefits - Risks - Protocol